Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC raised its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 195.6% during the 3rd quarter, Holdings Channel reports. The fund owned 21,753 shares of the biopharmaceutical company’s stock after purchasing an additional 14,394 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Ultragenyx Pharmaceutical were worth $1,208,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the business. Millennium Management LLC increased its stake in Ultragenyx Pharmaceutical by 103.8% in the 2nd quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock worth $76,065,000 after purchasing an additional 942,529 shares in the last quarter. Avoro Capital Advisors LLC grew its position in Ultragenyx Pharmaceutical by 137.1% during the 1st quarter. Avoro Capital Advisors LLC now owns 830,000 shares of the biopharmaceutical company’s stock worth $38,753,000 after purchasing an additional 480,000 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at $17,468,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Ultragenyx Pharmaceutical by 513.8% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock valued at $23,677,000 after buying an additional 424,476 shares during the period. Finally, Artal Group S.A. acquired a new position in Ultragenyx Pharmaceutical during the first quarter valued at $8,308,000. Institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the subject of several research reports. Wells Fargo & Company raised their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group reissued a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $85.17.

Insiders Place Their Bets

In related news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,556 shares of company stock worth $1,515,967 in the last 90 days. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 0.1 %

RARE opened at $51.06 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $34.06 and a 1-year high of $60.37. The stock has a market cap of $4.71 billion, a PE ratio of -6.99 and a beta of 0.58. The stock’s fifty day simple moving average is $55.58 and its 200 day simple moving average is $48.02.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.